Clarus Therapeutics Inc

Type: Company
Name: Clarus Therapeutics Inc
First reported Mar 21 2014 - Updated Mar 21 2014 - 1 reports

Biogen's Scangos joins Agilent board

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney ( email | Twitter ) or Emily Mullin ( email | Twitter ) and we will feature ... [Published FierceBiotech - Mar 21 2014]
First reported Mar 20 2014 - Updated Mar 20 2014 - 1 reports

Clarus Therapeutics appoints new COO

Clarus Therapeutics, Inc., a specialty pharmaceutical company, has appointed John Gargiulo as its new COO. Mr Gargiulo was most recently North American President and CEO of Daiichi Sankyo, Inc. He will report to Robert E. Dudley, President and CEO, and ... [Published Individual.com - Mar 20 2014]
First reported Mar 17 2014 - Updated Mar 17 2014 - 2 reports

Clarus Therapeutics Appoints Chief Operating Officer

(GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., a men's health specialty pharmaceutical company focused on the development and commercialization of REXTORO, an oral testosterone (T) replacement product, today announced that John P. Gargiulo has joined ... [Published BioSpace - Mar 17 2014]
First reported Mar 11 2014 - Updated Mar 11 2014 - 1 reports

Research and Markets: Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/96lvrm/testosterone) has announced the addition of the report to their offering.The report provides separate comprehensive analytics for the US, Canada, Europe, ... [Published CNBC - Mar 11 2014]

Quotes

>  Joseph Chalil joined Provectus Biopharmaceuticals " strategic advisoryadvisory board. Release"
"I look forward to working with the Clarus team as we seek to launch REXTORO in the US," Mr Gargiulo said. "REXTORO addresses a real desire among hypogonadal men for an oral treatment option that would eliminate the risk of T transference to women and children commonly associated with topical T gels or solutions. Hypogonadal men and their physicians are looking for a new therapeutic option and I believe that REXTORO has a great opportunity to be the preferred choice for them."

More Content

All (8) | News (5) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
Biogen's Scangos joins Agilent board [Published FierceBiotech - Mar 21 2014]
Clarus Therapeutics appoints new COO [Published Individual.com - Mar 20 2014]
Clarus Therapeutics Appoints Chief Operating Of... [Published BioSpace - Mar 17 2014]
Clarus Therapeutics Appoints John Gargiulo Chie... [Published GlobeNewswire: Acquisitions News - Mar 17 2014]
Clarus Therapeutics Appoints John Gargiulo Chie... [Published BusinessWeek - Mar 17 2014]
Research and Markets: Concise Analysis of the I... [Published CNBC - Mar 11 2014]
Clarus Therapeutics Submits New Drug Applicatio... [Published GlobeNewswire: Acquisitions News - Jan 13 2014]
Clarus Therapeutics Presents at 32nd Annual J.P... [Published GlobeNewswire: Advertising News - Jan 09 2014]
1
Content Volume
Document Volume
Network
Network

Press Releases

sort by: Date | Relevance
Clarus Therapeutics Appoints John Gargiulo Chie... [Published GlobeNewswire: Acquisitions News - Mar 17 2014]
Clarus Therapeutics Submits New Drug Applicatio... [Published GlobeNewswire: Acquisitions News - Jan 13 2014]
Clarus Therapeutics Presents at 32nd Annual J.P... [Published GlobeNewswire: Advertising News - Jan 09 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.